Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1986 1
1993 1
2000 1
2007 1
2011 1
2013 1
2016 1
2017 1
2018 5
2019 2
2020 2
2021 2
2022 2
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators. Hammond J, et al. N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16. N Engl J Med. 2022. PMID: 35172054 Free PMC article. Clinical Trial.
The cost-effectiveness of a resilience-based psychosocial intervention for HIV prevention among MSM in India.
Kazemian P, Ding DD, Scott JA, Feser MK, Biello K, Thomas BE, Dange A, Bedoya CA, Balu V, Rawat S, Kumarasamy N, Mimiaga MJ, O'Cleirigh C, Weinstein MC, Kumar JP, Kumar S, Mayer KH, Safren SA, Freedberg KA. Kazemian P, et al. Among authors: dange a. AIDS. 2022 Jul 15;36(9):1223-1232. doi: 10.1097/QAD.0000000000003231. Epub 2022 Apr 26. AIDS. 2022. PMID: 35471644 Free PMC article.
A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin.
Jain A, Vispute A, Dange A, Naskar A, Mondal A, Vivekanand B, Sharma B, Varade D, Shukla D, Bhatia G, Chaudhari H, Ram Babu K, Gavali O, Sorate S, Bhanushali S, Kothari V, Khandelwal V, Sharma A, Pawar R, Mayabhate M, Shahavi V, Rajput A, Jaiswal M. Jain A, et al. Among authors: dange a. Diabetes Ther. 2024 Jan;15(1):215-227. doi: 10.1007/s13300-023-01504-3. Epub 2023 Nov 14. Diabetes Ther. 2024. PMID: 37957465 Free PMC article.
Strengthening resilience to reduce HIV risk in Indian MSM: a multicity, randomised, clinical efficacy trial.
Safren SA, Thomas B, Biello KB, Mayer KH, Rawat S, Dange A, Bedoya CA, Menon S, Anand V, Balu V, O'Cleirigh C, Klasko-Foster L, Baruah D, Swaminathan S, Mimiaga MJ. Safren SA, et al. Among authors: dange a. Lancet Glob Health. 2021 Apr;9(4):e446-e455. doi: 10.1016/S2214-109X(20)30547-7. Lancet Glob Health. 2021. PMID: 33740407 Free PMC article. Clinical Trial.
A randomized clinical efficacy trial of a psychosocial intervention to strengthen self-acceptance and reduce HIV risk for MSM in India: study protocol.
Mimiaga MJ, Thomas B, Mayer KH, Regenauer KS, Dange A, Andres Bedoya C, Rawat S, Balu V, O'Cleirigh C, Biello KB, Anand V, Swaminathan S, Safren SA. Mimiaga MJ, et al. Among authors: dange a. BMC Public Health. 2018 Jul 18;18(1):890. doi: 10.1186/s12889-018-5838-2. BMC Public Health. 2018. PMID: 30021566 Free PMC article.
Efficacy and Safety of a Fixed-Dose Combination of Vildagliptin and Pioglitazone in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Comparative, Phase III Study.
Erande S, Mukhopadhyay J, Dange A, Deogaonkar A, Birla A, Doshi C, Revankar S, B SS, Kumar N, Kadam PV. Erande S, et al. Among authors: dange a. Cureus. 2023 Sep 1;15(9):e44548. doi: 10.7759/cureus.44548. eCollection 2023 Sep. Cureus. 2023. PMID: 37795066 Free PMC article.
ICARUS at the Fermilab Short-Baseline Neutrino program: initial operation.
Abratenko P, Aduszkiewicz A, Akbar F, Pons MA, Asaadi J, Aslin M, Babicz M, Badgett WF, Bagby LF, Baibussinov B, Behera B, Bellini V, Beltramello O, Benocci R, Berger J, Berkman S, Bertolucci S, Bertoni R, Betancourt M, Bettini M, Biagi S, Biery K, Bitter O, Bonesini M, Boone T, Bottino B, Braggiotti A, Brailsford D, Bremer J, Brice SJ, Brio V, Brizzolari C, Brown J, Budd HS, Calaon F, Campani A, Carber D, Carneiro M, Terrazas IC, Carranza H, Casazza D, Castellani L, Castro A, Centro S, Cerati G, Chalifour M, Chambouvet P, Chatterjee A, Cherdack D, Cherubini S, Chithirasreemadam N, Cicerchia M, Cicero V, Coan T, Cocco AG, Convery MR, Copello S, Cristaldo E, Dange AA, de Icaza Astiz I, De Roeck A, Di Domizio S, Di Noto L, Di Stefano C, Di Ferdinando D, Diwan M, Dolan S, Domine L, Donati S, Doubnik R, Drielsma F, Dyer J, Dytman S, Fabre C, Fabris F, Falcone A, Farnese C, Fava A, Ferguson H, Ferrari A, Ferraro F, Gallice N, Garcia FG, Geynisman M, Giarin M, Gibin D, Gigli SG, Gioiosa A, Gu W, Guerzoni M, Guglielmi A, Gurung G, Hahn S, Hardin K, Hausner H, Heggestuen A, Hilgenberg C, Hogan M, Howard B, Howell R, Hrivnak J, Iliescu M, Ingratta G, James C, Jang W, Jung M, Jwa YJ,… See abstract for full author list ➔ Abratenko P, et al. Among authors: dange aa. Eur Phys J C Part Fields. 2023;83(6):467. doi: 10.1140/epjc/s10052-023-11610-y. Epub 2023 Jun 4. Eur Phys J C Part Fields. 2023. PMID: 37303462 Free PMC article.
Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study.
Ajmani AK, Agrawal A, Prasad BLN, Basu I, Shembalkar J, Manikanth N, Subrahmanyam KAV, Srinivasa M, Chawla M, Srivastava MK, Jebasingh F, Achappa B, Agrawal RP, Pulichikkat RK, Meena R, Bhatia S, Gupta SK, Dange A, Srivastava A, Trailokya A, Shahavi V, Shende S. Ajmani AK, et al. Among authors: dange a. Diabetes Res Clin Pract. 2019 Nov;157:107860. doi: 10.1016/j.diabres.2019.107860. Epub 2019 Sep 14. Diabetes Res Clin Pract. 2019. PMID: 31526825 Clinical Trial.
26 results